studi
regard
loadindepend
effect
empagliflozin
contribut
improv
cardiac
function
experiment
heart
failur
reduc
eject
fraction
interest
thing
need
pay
attent
present
commentari
refer
recent
publish
articl
connelli
et
al
describ
empagliflozin
contribut
improv
cardiac
function
experiment
heart
failur
reduc
eject
fraction
hfref
empareg
outcom
demonstr
patient
type
diabet
high
risk
cardiovascular
event
receiv
empagliflozin
compar
placebo
lower
rate
primari
composit
cardiovascular
outcom
death
caus
studi
drug
ad
standard
care
underli
mechan
also
explor
shown
empagliflozin
improv
hemodynam
hypertens
heart
failur
rat
model
associ
renal
protect
attenu
cardiac
fibrosi
normal
hf
gene
glycaem
control
empagliflozin
significantli
amelior
myocardi
oxid
stress
injuri
cardiac
fibrosi
diabet
mice
drug
also
improv
primari
hemodynam
paramet
attenu
progress
atherosclerosi
reduc
hyperlipidemia
hyperglycemia
reduc
level
cardiotox
lipid
improv
autophagi
heart
zucker
diabet
fatti
rat
moreov
empagliflozin
improv
coronari
microvascular
function
contractil
perform
prediabet
obob
mice
attenu
ischemia
reperfus
injuri
signal
pathway
believ
import
necessari
analyz
report
potenti
underli
mechan
empagliflozin
benefit
heart
failur
especi
hfref
loaddepend
loadindepend
effect
studi
identifi
experiment
hfref
model
ligat
left
anterior
descend
coronari
arteri
induc
myocardi
infarct
left
ventricl
suggest
empagliflozin
major
benefici
effect
princip
loadindepend
measur
systol
function
preload
recruit
stroke
work
relationship
end
systol
pressur
volum
relationship
indic
salutari
effect
least
part
due
action
beyond
direct
effect
reduc
preload
afterload
thing
need
pay
attent
firstli
studi
establish
experiment
hfref
model
myocardi
infarct
although
post
myocardi
infarct
model
develop
structur
hallmark
hfref
mani
caus
hfref
ideal
model
heart
failur
warrant
addit
follow
confirm
infarct
size
echocardiographi
cardiovascular
diabetolog
correspond
njucmeducn
nanj
hospit
chines
medicin
affili
nanj
univers
chines
medicin
nanj
china
full
list
author
inform
avail
end
articl
post
myocardi
infarct
anim
random
receiv
vehicl
sodiumglucos
link
inhibitor
empagliflozin
mg
kgday
gavag
week
prior
random
administr
author
appli
echocardiographi
determin
infarct
size
confirm
structur
heart
eject
fraction
valu
typic
featur
phenotyp
hfref
thirdli
mgkgday
empagliflozin
administr
realli
much
rememb
dose
empagliflozin
mg
mg
daili
clinic
trial
translat
less
mgkgday
rat
final
experiment
studi
say
report
nonhuman
studi
need
evid
clinic
trial
confirm
hfref
heart
failur
reduc
eject
fraction
